Cargando…
2019–2020 Drug Updates in Hematologic Malignancies
During JADPRO Live Virtual 2020, Heidi D. Finnes, PharmD, BCOP, FHOPA, discussed the pharmacology and indications of medications approved from late 2019 to late 2020 for the management of patients with hematologic malignancies, reviewed pivotal clinical trial data, and covered the adverse events of...
Autor principal: | Finnes, Heidi D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087224/ https://www.ncbi.nlm.nih.gov/pubmed/34084575 http://dx.doi.org/10.6004/jadpro.2021.12.3.12 |
Ejemplares similares
-
2020–2021 Drug Updates in Hematologic Malignancies
por: Hanna, Kirollos
Publicado: (2022) -
2018–2019 Drug Updates in Hematologic Malignancies
por: Held, Lauren
Publicado: (2020) -
2021–2022 Drug Updates in Hematologic Malignancies
por: Tobin, Jenni
Publicado: (2023) -
2019–2020 Drug Updates in Solid Tumors
por: Hanna, Kirollos S.
Publicado: (2021) -
New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents
por: Harvey, R. Donald
Publicado: (2018)